Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Nephrology | Urology
Disease Category: Nocturia
Location: United States, IN

Clinical Trial Details


Research Study Summary

A randomized, double, placebo-controlled, parallel group study to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia.


SER120 will be administered intra-nasally as a single spray in either the left or right nostril each night before bedtime. The placebo will also be administered this same way.


  • Male or female > 50 years of age
  • Documented nocturia > 2 nocturic episodes/night for at least 6 months by history


  • Obstructive sleep apnea
  • Evidence of current UTI, bladder stone, bladder pain syndrome, or I.C.
  • History of urinary bladder surgery or radiotherapy within the last 24 months prior to enrollment
  • Severe daytime LUTS secondary to benign prostatic hypertrophy, OAB, or severe stress urinary incontinence

To Learn more

CW ID: 178191
Date Last Changed: May 2, 2014

Clinical Trial Snapshot

Both Male and Female
50 and up
Overall Status
Facility Type


Debbie Johnson, CCRC, Director of Research
First Urology, PSC
101 Hospital Blvd.
Jeffersonville, IN 47130
Phone: (812) 206-8161
Fax: (812) 288-2612

View Map

Research Center Information:

First Urology, PSC

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.